Nuvectis Pharma (NVCT) filed a shelf registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $150 million of securities from time to time.
The filing covers the sale of the company's common stock, preferred stock, warrants, debt securities, and units comprising any combination of those securities.